Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Leases (2019 - 2025)

Historic Current Leases for Anika Therapeutics (ANIK) over the last 7 years, with Q3 2025 value amounting to $1.7 million.

  • Anika Therapeutics' Current Leases fell 2473.82% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2473.82%. This contributed to the annual value of $1.9 million for FY2024, which is 498.08% up from last year.
  • Latest data reveals that Anika Therapeutics reported Current Leases of $1.7 million as of Q3 2025, which was down 2473.82% from $1.8 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Current Leases high stood at $2.3 million for Q3 2024, and its period low was $119000.0 during Q1 2021.
  • Its 5-year average for Current Leases is $1.8 million, with a median of $1.9 million in 2024.
  • In the last 5 years, Anika Therapeutics' Current Leases surged by 118403.36% in 2022 and then plummeted by 2473.82% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Current Leases stood at $1.5 million in 2021, then skyrocketed by 35.85% to $2.1 million in 2022, then dropped by 11.87% to $1.8 million in 2023, then rose by 4.98% to $1.9 million in 2024, then decreased by 10.06% to $1.7 million in 2025.
  • Its Current Leases stands at $1.7 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.9 million for Q1 2025.